Results 81 to 90 of about 3,528,989 (183)

Combination Strategies and Targeted Radionuclide Therapies

Seminars in Nuclear Medicine
Combination models utilising treatments from two or more therapeutic classes are well established in cancer care. In the new era of theranostic (theragnostic) medicine there is an ongoing need to identify and refine novel combination strategies to optimise multidisciplinary care for conditions commonly encountered in nuclear medicine such as ...
Kerry Jewell, Louise Kostos, Brittany Emmerson, Michael S. Hofman   +3 more
openaire   +3 more sources

Lead-212 Radiopharmaceuticals for Receptor-Targeted Radionuclide Therapy [PDF]

Journal of Mazandaran University of Medical Sciences
Receptor-targeted radionuclide therapy (RTRT) combines the power of particle-emitting radionuclides with the receptor-targeting capabilities of biomolecules, including antibodies and peptides.
Solmaz Mojarad-Jabali, Sajjad Molavipordanjani   +1 more
doaj  

Epigenetic Dysregulation of Somatostatin Receptors (SSTR) 1–5 and Therapeutic Implications in Neuroendocrine and Non‐Neuroendocrine Malignancies

International Journal of Cancer, Volume 159, Issue 11, Page 2633-2652, 1 December 2026.
ABSTRACT Somatostatin receptors (SSTR) mediate the antiproliferative, antisecretory, and proapoptotic effects of somatostatin and its synthetic analogs. Their surface expression on neuroendocrine tumor (NET) cells is required for somatostatin analog therapy and radiopharmaceutical therapy (RPT).
Neeraj Kumari, Pablo Hoffmann, Laura Reichl, Maximilian Schmutz, Nina Fischer, Thi Tuong Vi Dang, Fulvia Ferrazzi, Pascal Johann, Michaela Kuhlen, Constantin Lapa, Rainer Claus   +10 more
wiley   +1 more source

Development of Radioiodinated Tetrahydropyrazolopyridine Inhibitors Targeting mIDH

Journal of Labelled Compounds and Radiopharmaceuticals, Volume 69, Issue 13-14, November-December 2026.
Iodinated tetrahydropyrazolopyridine ligands show enhanced potency and selectivity for mutant IDH1 compared with their fluorinated counterparts and can be efficiently radiolabeled with I‐125, supporting the basis for further evaluation as mIDH1‐targeting radiotheranostic candidates.
Sarandeep Kaur, Sladjana Dukic‐Stefanovic, Lucie Arnaud, Jean‐Michel Chezal, Barbara Wenzel, Rareş‐Petru Moldovan, Klaus Kopka, Aurélie Maisonial‐Besset   +7 more
wiley   +1 more source

The current status and prospects of theranostic in targeted radionuclide therapy

肿瘤影像学
Targeted radionuclide therapy (TRT) leveraging the unique properties of radioactive pharmaceuticals to concentrate therapeutic effects within tumor tissues.
DING Ying, YANG Hui
doaj  

A DPP6‐Targeted PET Tracer for Non‐Invasive Imaging of Transplanted Human Islets

Diabetes, Obesity and Metabolism, Volume 28, Issue 12, Page 11676-11688, December 2026.
ABSTRACT Introduction Dipeptidyl peptidase‐like protein 6 (DPP6) is a potential molecular imaging biomarker for pancreatic and transplanted islets of Langerhans. 4hD29 is a single‐domain antibody with nanomolar affinity for DPP6. Here, we demonstrate the generation and validation of [68Ga]Ga‐NOTA‐4hD29 for Positron Emission Tomography (PET) imaging of ...
Amina Khalil, Arturo Roca‐Rivada, Svitlana Vasylovska, Lorenzo J. I. Balestri, Irina Velikyan, Sayro Jawurek, Alexandra C. Title, Burcak Yesildag, Luke R. Odell, Joey Lau, Decio L. Eizirik, Olof Eriksson   +11 more
wiley   +1 more source

Targeted Radionuclide Therapy

, 2022
The aim of this work is to improve the current computational dosimetry approaches for in vitro and in vivo TRT treatment in order to correlate microdosimetry with biological effects. The creation of such computational frameworks and the investigation of the radiobiology of dose-response in TRT in cells and in small animals can ultimately lead to a ...
openaire   +1 more source

Activities for the Development of Targeted Radionuclide Therapy in Japan [PDF]

Nuclear Medicine and Molecular Imaging, 2018
Targeted radionuclide therapy (TRT) is unique because of its efficacy and its theranostic feature in the era of precision medicine. So far, introduction of new TRT has not been going well in Japan due to several reasons including strict regulations, shortage of facilities for TRT, and insufficient reimbursement for TRT in clinic. Japanese community had
openaire   +2 more sources

Genomic Alterations in Pulmonary Carcinoid Tumors: A Targeted Analysis of Gene Rearrangements and Oncogenic Mutations

Cancer Medicine, Volume 15, Issue 11, November 2026.
This study applied RNA‐based next‐generation sequencing to one of the largest cohorts of pulmonary carcinoid tumors analyzed to date and revealed rare yet potentially actionable gene rearrangements and variants, including alterations in ALK, BRAF, and EGFR.
Jenni Niinimäki, Soili Kytölä, Ari Ristimäki, Johanna Arola, Tiina Vesterinen   +4 more
wiley   +1 more source

Acute Lymphopenia and Recovery With Prophylactic Pelvic Nodal Radiotherapy in Oligometastatic Prostate Cancer: Interim Results From the Prospective PROLONG2 Cohort

Cancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Background Prophylactic pelvic nodal radiotherapy (PRT) aims to eradicate occult pelvic nodal disease in oligometastatic prostate cancer but increases lymphocyte exposure. Its early hematologic safety and lymphocyte recovery when added to radiotherapy to the prostate/prostate region and all imaging‐visible metastases remain uncertain.
Xin Qi, Hewei Wang, Huan Zhang, Xueying Ren, Mingwei Ma, Xiaoying Li, Wanqi Zhang, Zhisong He, Yi Song, Cheng Shen, Wei Yu, Yu Fan, Xianshu Gao, Hongzhen Li   +13 more
wiley   +1 more source